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he progressive expansion of the Novel A (H1N1) v epi-
emic in the EpiSouth region (Mediterranean and Balkans)
. Ait Belghiti 1,∗, N. El Omeiri 1, J. Gueguen1, A. Rachas1,
. Gastellu-Etchegorry1, S. Declich2, M.-G. Dente2, P.
arboza1
Institut de Veille Sanitaire (InVS), Saint Maurice, France
Istituto Superiore di Sanita, Rome, Italy
Background: EpiSouth is a network covering 26 Mediter-
anean and Balkan countries. Since April 2009, all continents
ave been progressively affected by the A(H1N1)v inﬂuenza
andemic.
Methods: In the scope of the project, EpiSouth countries
hared, on a voluntary basis, information regarding their
onﬁrmed cases, case deﬁnitions and cases management
trategies. Data concerning conﬁrmed cases were analysed
n a weekly basis.
Results: The ﬁrst conﬁrmed case was reported on the
7th of April in Spain. As of 06 July 2009, 2,577 con-
rmed cases were reported by 24/26 countries. The most
ffected country was Spain (776 cases) followed by Israel
681) and France (330). The pandemic spread within the four
piSouth sub-regions was slightly different: the number of
ases started to increase markedly ﬁrst among EpiSouth EU
ountries (week 19), followed by Middle-East (week 23), and
nally North Africa and Balkans (Week 27).
These different dynamics can be partly explained by the
istorical or socio-economical links existing between coun-
ries. The more rapidly affected EpiSouth countries (e.g.
pain, Israel or France) are those with close links (e.g.
umerous direct daily ﬂights with the Americas) while coun-
ries with less direct or frequent connections could delay
onger the implementation of a local cycle of transmis-
ion. Later, population movements within EpiSouth countries
lso contributed to a further pandemic spread (e.g. cases
xported from France to Algeria, Slovenia and Tunisia and
rom Spain to Lebanon and Serbia). The third phase was
inked to relations with neighbouring areas e.g. Saudi Arabia
xported cases to several EpiSouth countries.
Conclusion: While all countries were faced with the same
ifﬁculties regarding implementation of control measures,
he ongoing information exchange between countries has
roven its importance.
oi:10.1016/j.ijid.2010.02.1707
8.038
n outbreak of inﬂuenza A pandemic (H1N1) 2009 in a res-
dential home for the disabled in Hong Kong and detection
f the ﬁrst local case of oseltamivir-resistant infection
.H.A. leung ∗, L.T.T. LOH
Centre for Health Protection, Hong Kong, China
Background: In Hong Kong, outbreaks of pandemic
nﬂuenza A (H1N1) virus infection occurred in institutions
ince June 2009. The Centre for Health Protection (CHP)
f the Department of Health carried out epidemiological
nvestigation and provided oseltamivir chemoprophylaxis for
esidents of residential home for the physically and mentally
o
1
D
mternational Congress on Infectious Diseases (ICID) Abstracts
isabled for conﬁrmed inﬂuenza outbreaks. We described
he epidemiological ﬁndings of an outbreak with a case of
seltamivir resistant infection detected.
Methods: We calculated the effectiveness of sea-
onal inﬂuenza vaccination 2008-2009 which comprised
/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007
H3N2)-like virus and B/Florida/4/2006-like virus in pro-
ection against pandemic inﬂuenza A (H1N1) 2009, and
he effectiveness of oseltamivir chemoprophylaxis. Thirty-
our respiratory specimens (15 nasopharyngeal aspirates,
5 nasopharyngeal swabs and 4 throat swabs) were taken
rom 34 residents for realtime RT-PCR testing for pandemic
nﬂuenza A (H1N1) 2009. All of the 21 positive samples were
urther tested for antiviral resistance.
Results: Seasonal inﬂuenza vaccination did not confer
rotection against pandemic inﬂuenza A (H1N1) virus (OR
.23, 0.70 to 7.00; p>0.05), but oseltamivir prophylaxis was
ound to be effective in preventing disease (OR 0.31, 0.10 to
.98; p<0.05). Overall compliance with oseltamivir chemo-
rophylaxis was satisfactory (94.5%). Two staff members
ho were offered oseltamivir reported early discontinuation
ue to side effects while two others did not start the med-
cation at all. Oseltamivir resistance in inﬂuenza A (H1N1)
irus infection was detected in one of the residents who had
een given oseltamivir prophylaxis for 6 days. There was no
vidence of spread of the resistant strain in the outbreak.
Conclusion: Oseltamivir chemoprophylaxis was effec-
ive in reducing the transmission of pandemic inﬂuenza
(H1N1) virus infection in long-term care facilities dur-
ng outbreak. Clinicians, microbiologists and public health
hysicians should be alerted to the possibility of emer-
ence of oseltamivir-resistant viruses in patients who have
eceived chemoprophylaxis.
oi:10.1016/j.ijid.2010.02.1708
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valuation of direct immunoﬂuorescent assay (DFA) and
apid antigen test (RAT) for diagnosis of new pandemic
nﬂuenza A H1N1 2009 (FLU AH1N1) during ﬁrst wave in
antiago, Chile
. Vizcaya1,∗, M. Ferrés2, C. Perret3, C. Martinez4, P.
odoy4, A.M. Contreras4, P. Ferrer4, T. Azocar4
Clinical Hospital of Catholic University, Santiago, Chile
Catholic University, Santiago, Chile
Pontiﬁcia Universidad Catolica de Chile, Santiago, Chile
Infectious diseases and Molecular Laboratory, Catholic
niversity, Santiago, Chile
Background: Since May 17th 2009 (epidemiological week
0th), the new strain of inﬂuenza A H1N1 was detected in
espiratory samples of symptomatic patients in Santiago,
hile. The circulation of the virus lasted 11 weeks, with a
eak between weeks 25-27th. The objective of our study was
o evaluate the performance of inﬂuenza tests for diagnosis
f FLU AH1N1.
Methods: Nasopharyngeal swabs were taken from in and
utpatients with inﬂuenza like illness (ILI), between June
st and July 19th of 2009 (weeks 23-29th) and the results of
FA and RAT were compared using RT-PCR FLU AH1N1 (Light
ix Kit Inﬂuenza A virus M2 and Light Mix Kit FLU A swine
